Accessibility navigation


Redox regulation of cardiac ASK1 (Apoptosis Signal-Regulating Kinase 1) controls p38-MAPK (Mitogen-Activated Protein Kinase) and orchestrates cardiac remodelling to hypertension

Meijles, D. N., Cull, J. J., Markou, T., Cooper, S. T. E., Haines, Z. H. R., Fuller, S. J., O'Gara, P., Sheppard, M. N., Harding, S. E., Sugden, P. H. and Clerk, A. (2020) Redox regulation of cardiac ASK1 (Apoptosis Signal-Regulating Kinase 1) controls p38-MAPK (Mitogen-Activated Protein Kinase) and orchestrates cardiac remodelling to hypertension. Hypertension, 76 (4). pp. 1208-1218. ISSN 1524-4563

[img]
Preview
Text (Open access) - Published Version
· Available under License Creative Commons Attribution.
· Please see our End User Agreement before downloading.

3MB
[img] Text - Accepted Version
· Restricted to Repository staff only

31MB
[img] Text - Supplemental Material
· Restricted to Repository staff only

1MB

It is advisable to refer to the publisher's version if you intend to cite from this work. See Guidance on citing.

To link to this item DOI: 10.1161/HYPERTENSIONAHA.119.14556

Abstract/Summary

Systemic hypertension increases cardiac workload causing cardiomyocyte hypertrophy and increased cardiac fibrosis. An underlying feature is increased production of reactive oxygen species (ROS). Redox-sensitive ASK1 activates stress regulated mitogen-activated protein kinases (p38-MAPK and JNKs) and promotes fibrosis in various tissues. Here, we determined the specificity of ASK1 signalling in the heart, with the hypothesis that ASK1 inhibitors may be used to manage fibrosis in hypertensive heart disease. Using immunoblotting, we established that moderate levels of H2O2 activate ASK1 in neonatal rat cardiomyocytes and perfused rat hearts. ASK1 was activated during ischemia in adult rat hearts, but not on reperfusion, consistent with activation by moderate (not high) ROS levels. In contrast, interleukin-1β (IL-1β) activated an alternative kinase, TAK1. ASK1 was not activated by IL1β in cardiomyocytes and activation in perfused hearts was due to increased ROS. Selonsertib (ASK1 inhibitor) prevented activation of p38-MAPKs (but not JNKs) by oxidative stresses in cultured cardiomyocytes and perfused hearts. In vivo (C57Bl/6J mice with osmotic minipumps for drug delivery), selonsertib (4 mg/kg/d) alone did not affect cardiac function/dimensions (assessed by echocardiography). However, it suppressed hypertension-induced cardiac hypertrophy resulting from angiotensin II (0.8mg/kg/d, 7d), with inhibition of Nppa/Nppb mRNA upregulation, reduced cardiomyocyte hypertrophy and, notably, significant reduction in interstitial and perivascular fibrosis. Our data identify a specific ROS→ASK1→p38-MAPK pathway in the heart and establish that ASK1 inhibitors protect the heart from hypertension induced cardiac remodelling. Thus, targeting the ASK1→p38-MAPK nexus has potential therapeutic viability as a treatment for hypertensive heart disease.

Item Type:Article
Refereed:Yes
Divisions:Faculty of Life Sciences > School of Biological Sciences > Biomedical Sciences
ID Code:92525
Publisher:American Heart Association, Inc

Downloads

Downloads per month over past year

University Staff: Request a correction | Centaur Editors: Update this record

Page navigation